Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage pharmaceutical company developing proprietary therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system. The ARTL news feed on Stock Titan aggregates company announcements, scientific updates, financing transactions, and regulatory disclosures that shape the outlook for its drug development programs.
Investors and observers following Artelo’s news can track progress across a diversified pipeline that includes ART27.13 for cancer anorexia and weight loss, ART26.12 as a Fatty Acid Binding Protein 5 (FABP5) inhibitor for chemotherapy-induced peripheral neuropathy and other potential indications, and ART12.11, a patented cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Company press releases highlight interim clinical data from the Cancer Appetite Recovery Study (CAReS), Phase 1 results for ART26.12, and preclinical findings supporting the therapeutic potential of FABP inhibition and pharmaceutical-grade CBD formulations.
The ARTL news stream also features peer-reviewed publication announcements, conference presentations at oncology and cannabinoid-focused meetings, and corporate developments such as executive appointments, cooperation agreements with shareholders, and capital-raising activities via public offerings, private placements, and at-the-market programs. Regulatory and listing-related updates, including communications about Nasdaq listing compliance, are disclosed through Form 8-K filings and associated press releases.
By reviewing Artelo Biosciences news on this page, readers can monitor key milestones in its clinical trials, scientific validation of its FABP and CBD platforms, and corporate actions that influence its financial and strategic position. Bookmark this feed to follow how Artelo’s lipid-signaling and endocannabinoid-targeted programs evolve through clinical, scientific, and capital markets events over time.
Artelo Biosciences (Nasdaq: ARTL) closed a private placement on March 30, 2026, issuing 3,188,407 shares (or pre-funded warrants) and warrants to buy up to 6,376,814 shares at a combined price of $3.45 per share/warrant, generating approximately $11.0 million gross proceeds before fees.
The company intends to use net proceeds for working capital, general corporate purposes, and repayment of certain bridge debt. If all warrants are exercised for cash, potential additional gross proceeds could be about $20.4 million; exercise is not assured.
Artelo Biosciences (Nasdaq: ARTL) entered definitive agreements for a private placement expected to close on or about March 30, 2026. The offering comprises 3,188,407 common shares (or pre-funded warrants) and warrants to buy 6,376,814 shares at $3.20, at a combined purchase price of $3.45 per unit.
Gross proceeds are expected to be approximately $11.0 million before fees; warrants could generate approximately $20.4 million if fully exercised. H.C. Wainwright is exclusive placement agent. Net proceeds will fund working capital, general corporate purposes, and repayment of bridge debt.
Artelo Biosciences (NASDAQ: ARTL) announced expansion of development for ART27.13 as a potential companion therapy to GLP-1 treatments on March 25, 2026. Key actions include a provisional patent filing, initiation of a non‑clinical study, publication of independent research, and supportive CAReS trial observations.
The company cites improvements in lean body mass and preclinical reversal of myotoxicity, positioning ART27.13 for muscle preservation alongside rapidly growing GLP-1 use.
Artelo Biosciences (NASDAQ: ARTL) expands ART27.13 into the $16.3B glaucoma market via a fully funded investigator-sponsored trial while advancing three clinical programs in oncology support, neuropathic pain, and CNS disorders.
Key advantages: positive Phase 2 signals, MHRA guidance for ART12.11, FABP inhibitor Phase 1 safety, European patent protection to 2041, and a $25M equity facility.
Artelo Biosciences (NASDAQ: ARTL) is expanding into glaucoma with a fully funded investigator-sponsored trial evaluating ART27.13, with first patient enrollment expected in Q2 2026. The move diversifies the pipeline without shareholder dilution and leverages a peripherally selective CB2-targeting mechanism. Key milestones include ongoing Phase 2 CAReS data and a European patent extending protection through December 2041. The global glaucoma market is projected to reach USD 16.31 billion by 2033, underscoring the commercial opportunity while noting typical early-stage clinical and regulatory risks.
Artelo Biosciences (Nasdaq: ARTL) entered a definitive investigator-initiated study agreement with Belfast Health and Social Care Trust to evaluate oral ART27.13 in glaucoma and ocular hypertension. The pilot, randomized cross-over study is funded by Glaucoma UK and HSC R&D, has ethics and MHRA approval, and expects first patient enrollment in Q2 2026. Artelo will supply ART27.13 capsules; the program tests a peripherally selective cannabinoid approach to lower intraocular pressure while avoiding central nervous system effects.
Artelo Biosciences (Nasdaq: ARTL) announced a 3-for-1 reverse stock split approved by the board on February 27, 2026. The split will combine every three outstanding shares into one and will be effective for trading on a split-adjusted basis at the open on March 10, 2026.
The company said the Board adopted the 3-for-1 ratio to increase the per-share price to improve marketability and liquidity. The new CUSIP after the reverse split will be 04301G706, and there will be approximately 708,258 shares issued and outstanding immediately after the split. All outstanding warrants and derivatives will automatically adjust per their terms.
Artelo Biosciences (Nasdaq: ARTL) reported clinical progress across three programs and fiscal 2025 year-end results dated February 24, 2026. Key clinical highlights include a positive Phase 1 SAD for ART26.12, positive interim Phase 2 CAReS data for ART27.13, and favorable UK MHRA guidance for ART12.11.
Financially, R&D was $5.4M, G&A $6.0M, net loss $12.9M ($12.52 per share), and cash and investments totaled $0.6M as of December 31, 2025.
Artelo Biosciences (Nasdaq: ARTL) commented on the Dec 23, 2025 White House Executive Order creating a Medicare pilot for cannabidiol (CBD) reimbursement and structured data collection.
Artelo said the initiative could improve access and generate data to inform research and potential Medicaid expansion. The company highlighted ART12.11, its patented CBD–tetramethylpyrazine cocrystal, stating superior oral bioavailability, more consistent pharmacokinetics, and enhanced efficacy signals in preclinical anxiety and depression models. Artelo reported the Drug Enforcement Agency indicated ART12.11 would not be considered a controlled substance and said it is prepared to complete final steps to advance ART12.11 into human clinical trials.
Artelo Biosciences (Nasdaq: ARTL) announced a peer‑reviewed publication (Dec 3, 2025) reporting that intraperitoneal dosing of its proprietary FABP5 inhibitor SBFI103 produced robust anxiolytic and antidepressant‑like effects in a validated chronic‑stress rat model.
Key experimental findings include single‑dose reductions in anxiety‑ and depression‑like behaviors with no locomotion or memory deficits, increased hippocampal expression of endocannabinoid‑related receptors CB2, GPR55, TRPV1, prevention of stress‑linked declines in depression biomarkers, and blockade of chronic‑stress effects on hippocampal neurogenesis.
The company funded the research; authors controlled study design and conclusions. Artelo said the data strengthen the rationale to advance FABP5 inhibitors (including ART26.12) toward human studies.